Cargando…

Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia

BACKGROUND: The prognosis of children with acute monocytic leukemia (AML‐M5) remains unsatisfactory and the risk profile is still controversial. We aim to investigate the prognostic value of clinical and cytogenetic features and propose a new risk stratification in AML‐M5 children. METHODS: We inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Li‐Peng, Zhang, Ao‐Li, Ruan, Min, Chang, Li‐Xian, Liu, Fang, Chen, Xia, Qi, Ben‐Quan, Zhang, Li, Zou, Yao, Chen, Yu‐Mei, Chen, Xiao‐Juan, Yang, Wen‐Yu, Guo, Ye, Zhu, Xiao‐Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286455/
https://www.ncbi.nlm.nih.gov/pubmed/32216042
http://dx.doi.org/10.1002/cam4.3023
_version_ 1783544879801958400
author Liu, Li‐Peng
Zhang, Ao‐Li
Ruan, Min
Chang, Li‐Xian
Liu, Fang
Chen, Xia
Qi, Ben‐Quan
Zhang, Li
Zou, Yao
Chen, Yu‐Mei
Chen, Xiao‐Juan
Yang, Wen‐Yu
Guo, Ye
Zhu, Xiao‐Fan
author_facet Liu, Li‐Peng
Zhang, Ao‐Li
Ruan, Min
Chang, Li‐Xian
Liu, Fang
Chen, Xia
Qi, Ben‐Quan
Zhang, Li
Zou, Yao
Chen, Yu‐Mei
Chen, Xiao‐Juan
Yang, Wen‐Yu
Guo, Ye
Zhu, Xiao‐Fan
author_sort Liu, Li‐Peng
collection PubMed
description BACKGROUND: The prognosis of children with acute monocytic leukemia (AML‐M5) remains unsatisfactory and the risk profile is still controversial. We aim to investigate the prognostic value of clinical and cytogenetic features and propose a new risk stratification in AML‐M5 children. METHODS: We included 132 children with AML‐M5. Overall survival (OS) and progression‐free survival (PFS) were documented. Cox regression was performed to evaluate the potential risk factors of prognosis. RESULTS: The 5‐year‐OS was 46.0% (95% confidence intervals, 41.6%‐50.4%) in all patients. There was significantly lower OS in the age ≤ 3 years old (P = .009) and hyperleukocytosis (P < .001). The FMS‐like tyrosine kinase 3 (FLT3)‐internal tandem duplication (ITD) and MLL‐rearrangement carriers were associated with fewer survivors in all patients (37.1% and 36.7%) and chemotherapy‐only group (19.0% and 35.0%). Notably, the number of survivor with MLL‐rearrangement did not increase in hematopoietic stem cell transplant (HSCT) group. According to the Cox regression analysis, HSCT was a significantly favorable factor (P = .001), while hyperleukocytosis, age ≤ 3 years old, and BM blast ≥ 70% adversely affected the OS in all patients (all P < .05). Additionally, FLT3‐ITD was a risk factor for OS in the chemotherapy‐only group (P = .023), while hyperleukocytosis and age ≤ 3 years independently contributed to poor PFS (both P < .05). In comparison to the standard‐risk group, significant poorer outcome was found in the high‐risk group (both P < .005). CONCLUSIONS: We propose that AML‐M5 children with any of MLL‐rearrangement, FLT3‐ITD, hyperleukocytosis, BM blast ≥ 70%, or age ≤ 3 years old are classified into the high‐risk group, and HSCT is beneficial especially in patients with FLT3‐ITD mutation, hyperleukocytosis, and age ≤ 3 years old. Importantly, the choice of HSCT should be made more carefully in children with MLL‐rearrangement for its suboptimal performance.
format Online
Article
Text
id pubmed-7286455
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72864552020-06-11 Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia Liu, Li‐Peng Zhang, Ao‐Li Ruan, Min Chang, Li‐Xian Liu, Fang Chen, Xia Qi, Ben‐Quan Zhang, Li Zou, Yao Chen, Yu‐Mei Chen, Xiao‐Juan Yang, Wen‐Yu Guo, Ye Zhu, Xiao‐Fan Cancer Med Clinical Cancer Research BACKGROUND: The prognosis of children with acute monocytic leukemia (AML‐M5) remains unsatisfactory and the risk profile is still controversial. We aim to investigate the prognostic value of clinical and cytogenetic features and propose a new risk stratification in AML‐M5 children. METHODS: We included 132 children with AML‐M5. Overall survival (OS) and progression‐free survival (PFS) were documented. Cox regression was performed to evaluate the potential risk factors of prognosis. RESULTS: The 5‐year‐OS was 46.0% (95% confidence intervals, 41.6%‐50.4%) in all patients. There was significantly lower OS in the age ≤ 3 years old (P = .009) and hyperleukocytosis (P < .001). The FMS‐like tyrosine kinase 3 (FLT3)‐internal tandem duplication (ITD) and MLL‐rearrangement carriers were associated with fewer survivors in all patients (37.1% and 36.7%) and chemotherapy‐only group (19.0% and 35.0%). Notably, the number of survivor with MLL‐rearrangement did not increase in hematopoietic stem cell transplant (HSCT) group. According to the Cox regression analysis, HSCT was a significantly favorable factor (P = .001), while hyperleukocytosis, age ≤ 3 years old, and BM blast ≥ 70% adversely affected the OS in all patients (all P < .05). Additionally, FLT3‐ITD was a risk factor for OS in the chemotherapy‐only group (P = .023), while hyperleukocytosis and age ≤ 3 years independently contributed to poor PFS (both P < .05). In comparison to the standard‐risk group, significant poorer outcome was found in the high‐risk group (both P < .005). CONCLUSIONS: We propose that AML‐M5 children with any of MLL‐rearrangement, FLT3‐ITD, hyperleukocytosis, BM blast ≥ 70%, or age ≤ 3 years old are classified into the high‐risk group, and HSCT is beneficial especially in patients with FLT3‐ITD mutation, hyperleukocytosis, and age ≤ 3 years old. Importantly, the choice of HSCT should be made more carefully in children with MLL‐rearrangement for its suboptimal performance. John Wiley and Sons Inc. 2020-03-26 /pmc/articles/PMC7286455/ /pubmed/32216042 http://dx.doi.org/10.1002/cam4.3023 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Liu, Li‐Peng
Zhang, Ao‐Li
Ruan, Min
Chang, Li‐Xian
Liu, Fang
Chen, Xia
Qi, Ben‐Quan
Zhang, Li
Zou, Yao
Chen, Yu‐Mei
Chen, Xiao‐Juan
Yang, Wen‐Yu
Guo, Ye
Zhu, Xiao‐Fan
Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia
title Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia
title_full Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia
title_fullStr Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia
title_full_unstemmed Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia
title_short Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia
title_sort prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286455/
https://www.ncbi.nlm.nih.gov/pubmed/32216042
http://dx.doi.org/10.1002/cam4.3023
work_keys_str_mv AT liulipeng prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT zhangaoli prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT ruanmin prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT changlixian prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT liufang prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT chenxia prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT qibenquan prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT zhangli prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT zouyao prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT chenyumei prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT chenxiaojuan prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT yangwenyu prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT guoye prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia
AT zhuxiaofan prognosticstratificationofmolecularlyandclinicallydistinctsubgroupinchildrenwithacutemonocyticleukemia